Mariwalla Dermatology, West Islip, New York.
Ava MD, Santa Monica, California.
Dermatol Surg. 2024 Sep 1;50(9S):S18-S23. doi: 10.1097/DSS.0000000000004332.
Botulinum toxin type A (BoNTA) is standard of care for glabellar lines ameliorization. DaxibotulinumtoxinA for Injection (DAXI) is a new BoNTA with a unique formulation representing the latest advancement in BoNTA technology. There is an unmet need for patients to understand the full potential of BoNTA treatment and new technologies.
To update clinical data supporting the use of DAXI for glabellar lines within the context of clinical experience.
A narrative review of the literature and summary of clinical experience with DAXI.
The DAXI clinical trial program reflects clinical experience post-FDA approval, with DAXI demonstrating rapid onset, high patient response rates, and extended treatment duration versus conventional BoNTAs. Clinical observations suggest that DAXI has limited diffusion from the injection site, enabling more localized control of muscle activity and greater improvements in wrinkle severity. DAXI enables practitioners to exert greater finesse in their injections and in predicting changes to eyebrow shape and position and achieve improvement in skin quality.
Advances in BoNTA technology can provide patients with greater options for treatment outcomes. The potential for enhanced localized effects with DAXI may contribute to more precise and targeted effects on muscle activity and additional aesthetic benefits to patients.
肉毒毒素 A 型（BoNTA）是改善眉间纹的标准治疗方法。注射用丹倍适肉毒毒素（DAXI）是一种新型 BoNTA，其独特的配方代表了 BoNTA 技术的最新进展。患者需要充分了解 BoNTA 治疗和新技术的潜力，但这方面的需求尚未得到满足。
根据临床经验，更新支持使用 DAXI 治疗眉间纹的临床数据。
对文献进行叙述性综述，并对 DAXI 的临床经验进行总结。
DAXI 临床试验计划反映了 FDA 批准后的临床经验，与传统 BoNTAs 相比，DAXI 显示出起效更快、患者应答率更高、治疗持续时间更长。临床观察表明，DAXI 从注射部位的扩散有限，能够更有效地控制肌肉活动，更显著地改善皱纹严重程度。DAXI 使医生在注射时能够更加精细，并预测眉形和位置的变化，从而改善皮肤质量。
BoNTA 技术的进步可以为患者提供更多的治疗效果选择。DAXI 具有增强的局部效应潜力，可能有助于更精确、更有针对性地影响肌肉活动，并为患者带来更多的美学益处。
